This is an application for a Research Supplement to Promote Diversity in Health-Related Research (PA-18-906). The parent R01 project associated with this application is entitled ?(PQ9) Developing EZH2 Degraders for Treating Triple-Negative Breast Cancer? supported by NCI (5R01CA230854-02). Brandon Dale is the diversity candidate. He is a US citizen of African-American descent and is currently an MD/PhD graduate student at Icahn School of Medicine at Mount Sinai, New York. The main goal of this study is to characterize a set of EZH2 degraders in triple-negative breast cancer cellular models.
EZH2 (enhancer of zeste homolog 2) is overexpressed in triple-negative breast cancer (TNBC) and high expression correlates with poor prognosis. EZH2 degraders, which pharmacologically reduce the EZH2 protein level in cells, could provide a potential therapeutic approach for treating TNBC. The proposed research is directly relevant to public health.
| Chiarella, Anna M; Wang, Tiffany A; Butler, Kyle V et al. (2018) Repressing Gene Transcription by Redirecting Cellular Machinery with Chemical Epigenetic Modifiers. J Vis Exp : |
